Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 S Neumann-Böhme, NE Varghese, I Sabat, PP Barros, W Brouwer, ... The European Journal of Health Economics 21, 977-982, 2020 | 1140 | 2020 |
Methods to determine reimbursement rates for diagnosis related groups (DRG): a comparison of nine European countries J Schreyögg, T Stargardt, O Tiemann, R Busse Health Care Management Science 9 (3), 215-223, 2006 | 315 | 2006 |
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches AK Buck, K Herrmann, T Stargardt, T Dechow, BJ Krause, J Schreyögg Journal of nuclear medicine technology 38 (1), 6-17, 2010 | 265 | 2010 |
United but divided: Policy responses and people’s perceptions in the EU during the COVID-19 outbreak I Sabat, S Neumann-Böhme, NE Varghese, PP Barros, W Brouwer, ... Health Policy 124 (9), 909-918, 2020 | 243 | 2020 |
Management im Gesundheitswesen: Das Lehrbuch für Studium und Praxis R Busse, J Schreyögg, T Stargardt Springer-Verlag, 2017 | 224* | 2017 |
Reforms in the Greek pharmaceutical market during the financial crisis S Vandoros, T Stargardt Health policy 109 (1), 1-6, 2013 | 147 | 2013 |
Defining the “Health Benefit Basket” in nine European countries J Schreyögg, T Stargardt, M Velasco-Garrido, R Busse The European Journal of Health Economics 6, 2-10, 2005 | 132 | 2005 |
Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries T Stargardt Health economics 17 (S1), S9-S20, 2008 | 117 | 2008 |
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment M Drummond, B Jönsson, F Rutten, T Stargardt The European Journal of Health Economics 12 (3), 263-271, 2011 | 116 | 2011 |
Availability of and Access to Orphan Drugs CR Blankart, T Stargardt, J Schreyögg Pharmacoeconomics 29 (1), 63-82, 2011 | 104 | 2011 |
Impact of Cross-Reference Pricing on Pharmaceutical Prices: Manufacturers Pricing Strategies and Price Regulation T Stargardt, J Schreyogg Applied Health Economics and Health Policy 5 (4), 235-247, 2006 | 94 | 2006 |
Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes T Stargardt, L Gonder-Frederick, KJ Krobot, CM Alexander Health Qual Life Outcomes 7, 91, 2009 | 89 | 2009 |
Patient‐reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain E Marrett, T Stargardt, P Mavros, CM Alexander Diabetes, obesity and metabolism 11 (12), 1138-1144, 2009 | 88 | 2009 |
Prevalence and determinants of probable depression and anxiety during the COVID-19 pandemic in seven countries: Longitudinal evidence from the European COvid Survey (ECOS) A Hajek, I Sabat, S Neumann-Böhme, J Schreyögg, PP Barros, ... Journal of affective disorders 299, 517-524, 2022 | 81 | 2022 |
Cost-effectiveness of hybrid PET/CT for staging of non–small cell lung cancer J Schreyögg, J Weller, T Stargardt, K Herrmann, C Bluemel, T Dechow, ... Journal of Nuclear Medicine 51 (11), 1668-1675, 2010 | 80 | 2010 |
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund S Weinbrenner, HJ Assion, T Stargardt, R Busse, G Juckel, CA Gericke Pharmacopsychiatry 42 (2), 66, 2009 | 77 | 2009 |
Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures NE Varghese, I Sabat, S Neumann-Böhme, J Schreyögg, T Stargardt, ... Plos one 16 (4), e0250872, 2021 | 71 | 2021 |
The Trade‐Off between Costs and Outcomes: The Case of Acute Myocardial Infarction J Schreyögg, T Stargardt Health Services Research 45 (6p1), 1585-1601, 2010 | 66 | 2010 |
Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching J Schreyögg, T Stargardt, O Tiemann Health Economics 20 (1), 85-100, 2011 | 65 | 2011 |
The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany T Stargardt The European Journal of Health Economics 11 (3), 267-277, 2010 | 64 | 2010 |